ProCE Banner Activity

Expert Selections From ASH 2020: Acute and Chronic Myeloid Leukemias

Conference Coverage
Clinical Thought
In this commentary, 2 experts discuss their top presentation choices from ASH 2020 in acute and chronic leukemias with the most potential to impact practice.

Released: March 03, 2021

Expiration: March 02, 2022

Share

Faculty

Jorge Cortes

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology

Faculty Disclosure

Primary Author

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

Jorge Cortes, MD, has disclosed that he has received funds for research support from Novartis, Pfizer, Sun Pharma, and Takeda and consulting fees from Novartis, Pfizer, and Takeda.

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie, Astellas, Bristol-Myers Squibb/Celgene, Genentech, Jazz, Kite, MacroGenics, Novartis, Pfizer, and Stemline and fees for non-CME/CE services from Dava Oncology, Pfizer, and Stemline.